Navigation Links
Early detection of cancer: The FDA approves procedure discovered by EPFL researchers

Researchers at the Ecole Polytechnique Fdrale de Lausanne (EPFL) in Switzerland have established a procedure where cancerous tumors in the bladder become fluorescent and are more easily discoverable under blue light. The Food and Drug Administration (FDA) approved the technique already in practice in Europe for the American market. Under the name Cysview, the product is commercialized by Photocure and GE Healthcare as the most efficient detection technique for early stage bladder cancer.

Bladder cancer is the fourth most common cancer in men and the eighth most common in women in the US. Being extremely difficult to detect in its early stages, even by the trained eye of a urologist, the importance of increasing its detectability is paramount for the complete removal of the tumors which helps to delay tumor recurrence.

Helping diagnostics and surgical removal

Cysview is instilled in the bladder. After penetrating the bladder wall it is metabolized mainly by the malignant cells, causing them to produce a fluorescent compound. The doctor then examines the bladder with an endoscope camera equipped with a blue light system: the tumors appear as easily-recognizable red spots. The procedure is not only helpful in diagnosing cancer, it is also useful for the surgeon when removing these small tumors, as he can be assured that the tumor is completely removed when no fluorescence remains.

"With Cysview, even a child can recognize these tumors", says Hubert van den Bergh, head of the project at EPFL. Then, he shows several examples where tumors have been forced out of hiding.

American experts have noticed a significant improvement with Cysview, compared to standard white light cystoscopy. A fact that is also supported in Europe with Hexvix, the European name for the product: experts have shown that the rate of recurrence of bladder cancer is significantly lower after treatment.

Application to other types of cancers

"In the future, similar procedures could be used, for instance for colon cancer or other tumors found in the hollow organs", explains Hubert van den Bergh. EPFL's Norwegian partner Photocure, owner of Hexvix/Cysview, is currently involved in developing this domain.

For the moment, this procedure is the only one of its kind approved by the FDA for use in the bladder. "There is no procedure as efficient," insists Georges Wagnires, responsible for the technology transfer in this project at EPFL, "and the market is therefore potentially very large." The approval by the FDA comes after a more than a decade of development work by the scientists at EPFL and their academic partners from the University Hospital Center (CHUV), the University of Lausanne and Photocure.


Contact: Georges Wagnires
Ecole Polytechnique Fdrale de Lausanne

Related medicine news :

1. Nuvo Research announces early redemption of 5% convertible debentures
2. A better sign of blood vessel narrowing and early coronary artery disease
3. Bad Behavior as a Kid Linked to Early Death in Men
4. Promising new neuroimaging techniques for early detection of Alzheimers disease
5. Symptoms have little value for early detection of ovarian cancer
6. Immune memory formation seen in early stages of viral infection
7. Symptoms Alone Dont Spot Ovarian Cancer Early
8. Early Factors Predict Later-Life Stroke Risk, from the Harvard Health Letter
9. Early menopause can result in earlier onset dementia
10. New Test Might Smell Early Stage Lung Cancer
11. Early EKG Seems to Improve Odds After Heart Attack
Post Your Comments:
Related Image:
Early detection of cancer: The FDA approves procedure discovered by EPFL researchers
(Date:11/27/2015)... ... 27, 2015 , ... Dr. Thomas Dunlap and Dr. Patrick ... Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital ... present in similar ways and require time-critical intervention to avoid large area heart damage ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) ... supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk ...
(Date:11/26/2015)... Las Vegas, NV (PRWEB) , ... November 26, 2015 , ... ... holiday shopping strategy. Many customers choose to buy during the Black Friday and ... holiday gifts. Shoppers don’t need to search the Internet high and low to find ...
(Date:11/26/2015)... ... 2015 , ... Somu Sivaramakrishnan announced today that he joined ... offers travelers, value and care based Travel Services, including exclusive pricing on a ... cabin upgrades and special amenities such as, shore excursions, discounted fares, travel gifts ...
(Date:11/26/2015)... Omaha, NE (PRWEB) , ... November 26, 2015 , ... ... careers searched by healthcare professionals and offered by healthcare staffing agency Aureus Medical ... top during the month of October 2015 among those searching for healthcare jobs through ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... -- Linden Care, LLC, a retail specialty pharmacy focused on ... from chronic pain, said today that it is disappointed ... enjoining Express Scripts from unilaterally terminating the Pharmacy Provider ... --> The company said that it ... --> --> In the ...
(Date:11/25/2015)... -- ARKRAY USA , Inc., a leader ... the accuracy of its blood glucose meter systems. Last ... and Cardiovascular Disease in Los Angeles ... 01 meter and the Assure ® Prism ... accurately measure glucose levels in blood is essential for ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc (NYSE: ... agreement with the New York State ... of the Sherman Act, and other statutes with the Attorney ... February 2014, to cease marketing and selling the now generic ... settlement, Allergan admits no liability, has released its counterclaims against ...
Breaking Medicine Technology: